东曜药业

TOT BIOPHARM International Company Limited

東曜藥業股份有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1875)

VOLUNTARY ANNOUNCEMENT

ENTERING INTO OF A SUPPLEMENTAL AGREEMENT WITH A WHOLLY-OWNED SUBSIDIARY OF ZHAOKE OPHTHALMOLOGY FOR DRUG MARKETING LICENSING, DEVELOPMENT AND COMMERCIALIZATION OF TAB014

This announcement is made by TOT BIOPHARM International Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that TOT BIOPHARM Co., Ltd. (東曜藥業有限公司, "**TOT Suzhou**"), a wholly-owned subsidiary of the Company, has entered into a supplemental agreement (the "**Supplemental Agreement**") with Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited (兆科(廣州)眼科藥物有限公司, "**Zhaoke Guangzhou**"), a wholly-owned subsidiary of Zhaoke Ophthalmology Limited (兆科眼科有限公司, "**Zhaoke Ophthalmology**", stock code: 6622), pursuant to which Zhaoke Guangzhou will act as the applicant in the making of the application to the National Medical Products Administration (NMPA) of China in respect of the marketing approval for TAB014 and be responsible for conducting Phase III clinical trials, and will act as the marketing authorization holder (MAH) throughout the product lifecycle of

TAB014 in China (including Hong Kong and Macau regions). All pre-clinical and clinical research data will remain to be jointly owned by Zhaoke Guangzhou and TOT Suzhou. After obtaining marketing approval, TOT Suzhou will still be responsible for the commercial-scale manufacturing of TAB014 and Zhaoke Guangzhou will still be responsible for the commercialization and distribution of TAB014 in the aforesaid licensed regions.

As disclosed in the prospectus dated 29 October 2019 published by the Company, in January 2017, TOT Suzhou entered into a product licensing, development and commercialization agreement with Zhaoke Guangzhou (the "**Original Agreement**"). Pursuant to the Supplemental Agreement, in light of the adjustment to the mode of collaboration, the payment schedule of the commercialization milestone payments under the Original Agreement was also adjusted accordingly such that it is primarily tied to the regulatory approval progress of TAB014, while the total milestone payment amount remains the same as that in the Original Agreement.

The Board is of the view that the entering into of the Supplemental Agreement is conducive to speeding up the development, marketing and commercialization of TAB014 in China. The Group will continue to give full play to its advantages in the commercial production of antibody drugs to manufacture high-quality drugs for all eye disease patients and to benefit eye disease patients in China.

ABOUT TOT SUZHOU

TOT Suzhou is a limited liability company incorporated in China and is a wholly-owned subsidiary of the Company. The Company is an investment holding company incorporated in Hong Kong with limited liability, whose shares are listed on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") (stock code: 1875). The Group is principally engaged in the research and development, manufacturing and marketing of oncology drugs in China with a large-scale production base for the commercialization of biological drugs that complies with international standards.

ABOUT ZHAOKE GUANGZHOU

Zhaoke Guangzhou is a limited liability company incorporated in China and is a wholly-owned subsidiary of Zhaoke Ophthalmology. Zhaoke Ophthalmology, whose shares are listed on the Stock Exchange (stock code: 6622), is an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs in China. Leveraging its deep domain expertise, Zhaoke Ophthalmology has built a comprehensive ophthalmic drug pipeline of at least 25 candidates that covers most major ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing.

At the time when the Original Agreement was entered into, Zhaoke Guangzhou was a wholly-owned subsidiary of Lee's Pharmaceutical Holdings Limited (李氏大藥廠控股有限公司) ("**Lee's Pharm**"), whose shares are listed on the Stock Exchange (stock code: 950). Since then, Lee's Pharm has carried out a spin-off and separate listing of Zhaoke Ophthalmology on the Stock Exchange. As at the date of this announcement, based on public information, Lee's Pharm is the single largest shareholder of Zhaoke Ophthalmology, indirectly holding approximately 26% of the total issued share capital of Zhaoke Ophthalmology.

To the best knowledge, information and belief of the Board having made all reasonable enquiries, Zhaoke Ophthalmology and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")).

ABOUT TAB014

TAB014 (recombinant humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody) is an ophthalmic formulation of bevacizumab for the treatment of wet (neovascular) age-related macular degeneration ("**wAMD**"), retinal vein occlusion (RVO), choroidal neovascularization (CNV) and other eye diseases. Among these, the main pathological feature of wAMD is choroidal angiogenesis in the macula, with VEGF playing an important role in the angiogenesis process. TAB014 is able to bind specifically to VEGF and block it from binding to its receptors, thereby inhibiting angiogenesis. TAB014 will eventually be administered as an intravitreal injection for the treatment of wAMD.

wAMD is a leading cause of vision loss and blindness in people over 50 years old in China and globally. According to China Insights Consultancy (CIC), the market size of wAMD drugs in China is forecast to increase from US$241.5 million to US$3.5 billion from 2019 to 2030, at a compound annual growth rate of 27.5%. TAB014 is the first bevacizumab-based antibody under clinical development indicated for wAMD in China.

The clinical research and commercialization project in relation to TAB014 was listed by the Development Center for Medical Science & Technology of the National Health Commission of China as a special major project for technologies of innovative manufacturing of major new drugs at the end of 2019.

Cautionary statement required by Rule 18A.05 of the Listing Rules: The Company cannot guarantee that it will be able to develop, or ultimately market, TAB014 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the securities of the Company.

By order of the Board
TOT BIOPHARM International Company Limited
Dr. Liu, Jun
Chief Executive Officer and Executive Director

Hong Kong, 9 March 2022

As at the date of this announcement, the executive directors of the Company are Dr. Liu, Jun and Ms. Yeh-Huang, Chun-Ying; the non-executive directors of the Company are Mr. Fu, Shan, Dr. Kung, Frank Fang-Chien, Mr. Kang, Pei and Mr. Qiu, Yu Min; and the independent non-executive directors of the Company are Ms. Hu, Lan, Dr. Sun, Lijun Richard and Mr. Chang, Hong-Jen.